Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials

Ignace Vergote and colleagues published consensus recommendations on methodological aspects of ovarian cancer clinical trials,1 which constitute a great achievement to harmonise their designs and will represent a valuable resource for ovarian cancers investigators.